SABCS 2022: Trials Show Improved Outcomes in HR+, HER2- Breast Cancer
The CAPItello-291, monarchE, RIGHT Choice, and EMERALD trials have shown favorable outcomes for patients with HR+, HER2- breast cancer.
All articles by Alan P. Lyss, MD
Differences in Tumor Biology Could Partly Explain Disparities in Metastatic NSCLC
Differences in tumor characteristics could explain sex- and race-based disparities in patients with metastatic non-small cell lung cancer.
Up to 10% of Early-Onset mCRC Cases May Be Driven by Undiagnosed IBD
As many as 10% of early-onset metastatic colorectal cancer cases may be attributable to undiagnosed inflammatory bowel disease, a study suggests.
Duration of ET Tied to Benefit in DCIS, but Young Patients May Reject ET
Two new studies shed light on the complexity of preventing subsequent breast cancer events in patients with ductal carcinoma in situ.
Crisis in Oncology Research Demands Urgent Action, Stakeholders Say
At a SITC summit, stakeholders identified administrative, staffing, and other barriers that impede progress in clinical cancer research.
Blood Test Shows Promise for Detecting Cancers Without Approved Screening Tests
A novel blood test can detect cancers that currently have no standard screening procedures, a study suggests.
Rising Costs of Oral Anticancer Drugs Burden Medicare Recipients; New Law May Provide Some Relief
New data highlight the high cost of targeted oral anticancer medicines for patients with Medicare Part D coverage.
Sublobar Resection Should Be New Standard Care for Certain Patients With NSCLC
Sublobar resection is noninferior to a full lobectomy in patients with carefully staged cT1aN0 non-small cell lung cancer, new research suggests.
How to Improve Outcomes for Older Patients With Ovarian Cancer
An expert outlines ways to improve outcomes for older patients with ovarian cancer.
Medicaid Expansion May Have Improved Access to Cancer Trials
The expansion of Medicaid eligibility was associated with a nearly 3-fold increase in the proportion of Medicaid-covered patients enrolled in cancer treatment trials.
- Loading...
Loading...
Next post in ASCO 2022
Loading... 
Loading...